848 hasil

Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report

David John McMahon, MD; Alexius John, MD; Foteini Kalofonou, PhD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 3 · 2026 · Inggris · DOAJ Scopus

A number of drugs are in development for the treatment of ERBB2(HER2)-mutated NSCLC, including antibody-drug conjugates such as trastuzumab-deruxtecan and tyrosine kinase inhibitors such as zongertinib and sevabertinib. Herein, we report a case of relapsed advanced ERBB2-mutant NSCLC with acquired…

ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report

Charles Hsu, MD; Mohamed Yakoub, MD, PhD; Michael Offin, MD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 3 · 2026 · Inggris · DOAJ Scopus

Background: ALK fusion-positive NSCLC is driven by a range of fusion partners, most often EML4::ALK. The clinical impact, oncogenicity, and resistance mechanisms of rare, noncanonical ALK fusions remain underexplored. We describe two previously unreported ALK fusion partners in NSCLC and explore…

Treatment Patterns in Early Stage NSCLC in Asia: Findings From the ELEVATE Study

Myung-Ju Ahn, MD, PhD; Daniel SW. Tan, BSc, M.B.B.S., MRCP, PhD; Morgan Windsor, FRACS dkk.

JTO Clinical and Research Reports, Vol. 7 No. 3 · 2026 · Inggris · DOAJ Scopus

Introduction: The management of early stage NSCLC is evolving with new therapies. Given the lack of guidelines for Asia Pacific, understanding the different factors affecting treatment decisions is key to effective clinical practice. This cross-sectional study describes management patterns for…

Immune Doublet Checkpoint Inhibition in EGFR-Mutated NSCLC: A Fire That Fails to Illuminate the Orchard

Richard Pham, MBBS; Surein Arulananda, MBBS, PhD

JTO Clinical and Research Reports, Vol. 7 No. 3 · 2026 · Inggris · DOAJ Scopus

Adjuvant Larotrectinib in a Resected Secretory Carcinoma-Like Lung Adenocarcinoma Harboring EML4-NTRK3 Fusion: Case Report

Vladmir Cláudio Cordeiro de Lima, MD, PhD; Breno Jeha Araújo, MD; Felipe D' Almeida Costa, MD, PhD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 3 · 2026 · Inggris · DOAJ Scopus

Secretory carcinoma of the lung is an exceptionally rare salivary gland-type malignancy, typically associated with NTRK fusions. We report a 71-year-old woman with pulmonary stage IIIA adenocarcinoma having salivary gland differentiation and solid-cribriform architecture, confirmed by S100 and…

Detection of a Rare Intra-ALK Inversion and ALK Rearrangement in a Lung Adenocarcinoma Patient by FoundationOne Liquid CDx and Successful Treatment with Alectinib: Case Report

Chiaki Kanno, MD, PhD; Satoshi Takahashi, MD, PhD; Masaru Hagiwara, MD, PhD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 3 · 2026 · Inggris · DOAJ Scopus

A 50-year-old woman with stage IVB lung adenocarcinoma tested negative for driver mutations using the Oncomine Dx Target Test Multi-CDx system (Thermo Fisher Scientific, Waltham, MA). After undergoing chemotherapy and immunotherapy, FoundationOne Liquid CDx (Foundation Medicine, Inc., Cambridge…

MET-Driven Resistance to Sotorasib in KRAS G12C–Mutant NSCLC and Response to Combined KRAS and MET Inhibition

Richard Riedel, MD; Lea Ruge, MD; Malte Verheyen, MD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 3 · 2026 · Inggris · DOAJ Scopus

Introduction: KRAS G12C mutations define a molecularly distinct subset of NSCLC for which targeted therapy with sotorasib has exhibited clinical efficacy. However, acquired resistance is inevitable. MET amplification has been described as a putative off-target resistance mechanism, although its…

Histologic Grade 3 in Stage 1A Lung Adenocarcinoma: Survival Risks Comparable to Stage 1B

Gyerim Park, MD; Youngkyu Moon, MD, PhD; Meejeong Kim, MD, PhD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 3 · 2026 · Inggris · DOAJ Scopus

Introduction: Early stage NSCLC presents a significant risk of recurrence despite surgical resection. The International Association for the Study of Lung Cancer–proposed histologic grading system identifies high-grade tumors (≥20% solid, micropapillary, or complex glandular patterns) as a potential…

Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study

Masayuki Shirasawa, MD, PhD; Makoto Nishio, MD, PhD; Kadoaki Ohashi, MD, PhD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 3 · 2026 · Inggris · DOAJ Scopus

Introduction: Effective predictors of response to atezolizumab plus carboplatin/etoposide (CE) therapy in extensive-stage SCLC (ES-SCLC) remain limited. This exploratory analysis from J-TAIL-2 aimed to identify markers of survival benefit with atezolizumab plus CE therapy in ES-SCLC. Methods…

Calling With One Voice—Alignment of Strategy for Lung Cancer in Patients of African Descent

Emily Stone, M.B.B.S., PhD, FRACP

JTO Clinical and Research Reports, Vol. 7 No. 3 · 2026 · Inggris · DOAJ Scopus

First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report

Kaiwen Wang, PharmD; Ceylan Altintas Taslic, MD; Patricia de Groot, MD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 2 · 2026 · Inggris · DOAJ Scopus

Small cell transformation has been described as a resistance mechanism to targeted therapy treated in patients with EGFR-mutated NSCLC and less often reported with those with other actionable oncogenic alterations, including ALK-rearranged NSCLC. Given lack of standard-of-care treatments for…

FDG-PET/CT SUVmax Predicts Recurrence Risk of Resected Pleuropulmonary Solitary Fibrous Tumors

Matthew Aizpuru, MD; Jennifer M. Boland, MD; Brendan W. Lunn, MD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 2 · 2026 · Inggris · DOAJ Scopus

Objectives: Risk stratification of pleuropulmonary solitary fibrous tumors (SFTs) is based on post-resection histopathologic scoring systems. We queried whether preoperative 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) maximum standardized uptake values…

The Landscape of CEACAM5 Expression by Immunohistochemistry in NSCLC

Ying-Han R. Hsu, MD, FRCPC; Amna Almutrafi, MD; Katrina Hueniken, MSc dkk.

JTO Clinical and Research Reports, Vol. 7 No. 2 · 2026 · Inggris · DOAJ Scopus

Introduction: Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a target of antibody-drug conjugate therapy for NSCLC. High expression of CEACAM5 has been reported in approximately 25% of patients with lung adenocarcinoma. However, CEACAM5 expression has not been systematically…

Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial

Niels Reinmuth, MD; Sébastien Couraud, MD, PhD; Luis Paz-Ares, MD, PhD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 2 · 2026 · Inggris · DOAJ Scopus

Introduction: In the phase 3 EVOKE-01 trial (NCT05089734), sacituzumab govitecan (SG) exhibited a numerical improvement in overall survival and tolerability compared with docetaxel in patients with metastatic NSCLC previously treated with platinum-based chemotherapy and programmed cell death…

Curative-Intent Multimodality Treatment for NSCLC: Will Global Healthcare Systems Rise to the Challenge? A Perspective From the United Kingdom

Matthew Evison, MD, MRCP; Shobhit Baijal, MBBS, BSc (Hons); Mayuri Basnet, MBBS, FRCPath dkk.

JTO Clinical and Research Reports, Vol. 7 No. 2 · 2026 · Inggris · DOAJ Scopus

Thymic Neuroendocrine Tumors: Evolving Insights and Innovative Approaches

Erica Pietroluongo, MD, PhD; Christine M. Bestvina, MD; Rachel Brattin dkk.

JTO Clinical and Research Reports, Vol. 7 No. 2 · 2026 · Inggris · DOAJ Scopus

Introduction: Thymic neuroendocrine tumors (TNENs) are exceptionally rare and a clinically heterogeneous malignancy, often diagnosed at an advanced stage and lacking standardized treatment algorithms. Due to the scarcity of dedicated evidence, most therapeutic strategies are extrapolated from other…

Pathologic Responses to Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early Stage NSCLC: A Phase 2 Study

Gustavo Schvartsman, MD, PhD; Yasmin M. Amirato, MD; Frederico Monfardini, MSc dkk.

JTO Clinical and Research Reports, Vol. 7 No. 2 · 2026 · Inggris · DOAJ Scopus

Introduction: Stereotactic ablative radiotherapy (SABR) is routinely used in patients with early stage NSCLC who are not candidates for surgery. Despite excellent local tumor control, it is associated with a high rate of regional and distant recurrences. Combining stereotactic radiotherapy with…

Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA)

Grace Chazan, FRACP; Marliese Alexander, PhD; Fanny Franchini, PhD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 2 · 2026 · Inggris · DOAJ Scopus

Introduction: Advanced lung cancer has historically been associated with poor survival. However, with the advent of targeted therapies, outcomes are improving. Among patients with ALK-rearranged advanced NSCLC (ALK+ aNSCLC), real-world data on treatment patterns, prognostic factors, and survival in…

Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data

Madhusmita Behera, PhD; Gregory Joseph, MS; Manali Rupji, MS dkk.

JTO Clinical and Research Reports, Vol. 7 No. 2 · 2026 · Inggris · DOAJ Scopus

Introduction: Precision medicine has resulted in improved outcomes for non small cell lung cancer (NSCLC), whereas biomarker testing is considered critical for guiding treatment decisions for advanced-stage NSCLC, and adoption of testing in routine practice is variable. We studied the utilization…

Erratum to ‘Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer’ [JTO Clinical and Research Reports 7 (2026) 101019]

Alisa K. Sivapiromrat, BS; Meredith J. McAdams, MD; Renee N. Donahue, PhD dkk.

JTO Clinical and Research Reports, Vol. 7 No. 9 · 2026 · Inggris · DOAJ Scopus